Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Paul Knight
Period: Reporting periods mapped to calendar 2024 Q4 – 2026 Q2 (7 quarters).
- Questions
- 9on tracked calls
- Challenge rate
- 0%none of 9 questionsLimited sample
- Companies
- 1questioned at least once
- Reporting periods
- 7with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 9 of 9 questions from 1 company
WSTWest Pharmaceutical Services9 questions · 7 reporting periods · 0 of 9 challenging
Calendar 2026 Q2
Dublin, the biggest, of course, where are you at with capacity utilization at Dublin.
Show response
Eric detailed productivity gains at Eschweiler, near-target throughput at Grand Rapids, and continued ramp with more available capacity at Dublin.
Calendar 2026 Q1
are there any bottlenecks that you see right now? And second, how easy is it for customers to move from one site
Show response
Eric explained three-pronged approach: higher throughput on existing capacity, qualifying multi-sites (6-12 months per transfer), and transferring learnings across network. Bob emphasized leveraging existing assets provides near-term benefit.
Calendar 2025 Q4
The Grand Rapids and the Dublin sites, where are they in kind of ramp-up stage? Are they at
Show response
Eric characterized Grand Rapids as near peak volumes with some room for 2026 improvement. Dublin still ramping auto-injectors and pens, with drug handling just commenced and expected to ramp over next 12-24 months. Bob confirmed Dublin drug handling $20M is early-stage, significantly larger at peak.
Calendar 2025 Q3
As you think about your long-term construct of 7% to 9% growth, are we heading there in 2026 in your opinion in terms of the momentum you're citing
Show response
Eric confirmed the long-range plan relies on HVP components driving double-digit growth through biologics, Annex-1, and GLP-1. Bob added the street is in a good place on estimates.
Calendar 2025 Q2
you mentioned that Crystal Zenith was a component of the growth. What was driving Crystal Zenith
Show response
Eric attributed CZ growth to a specific drug launch with an element of timing, while noting continued broader customer interest in the product.
Calendar 2025 Q1
at what percent utilization are you assuming in the new site in Dublin, Eric, in your guidance?
Show response
Eric confirmed Dublin utilization is quite low currently with ramp-up progressing and drug handling expected end of year/early next year.
your margin seems to have been a little bit better on the adjusted op margin in 1Q. Is it business mix
Show response
Bernard attributed margin improvement to better efficiencies in proprietary products, contract manufacturing, and controlled SG&A/R&D spending.
Calendar 2024 Q4
Is it at half of capacity for the year? What's your kind of view on what it's going to be producing
Show response
Bernard indicated Dublin auto-injector ramp back-half weighted, with drug handling capability coming online late 2025/early 2026.
You have had a long-term guide of our construct of a 7% to 9% organic growth
Show response
Eric expressed strong conviction in returning to 7-9% organic growth, driven by multiple customers, drugs, and categories normalizing.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| WST West Pharmaceutical Services | 9 | 0%none of 9 questions |
- WSTWest Pharmaceutical Services · 9 questions0%none of 9 questions
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q4 | 2 | 0%none of 2 questions | 1 |
| 2025 Q1 | 2 | 0%none of 2 questions | 1 |
| 2025 Q2 | 1 | 0%none of 1 question | 1 |
| 2025 Q3 | 1 | 0%none of 1 question | 1 |
| 2025 Q4 | 1 | 0%none of 1 question | 1 |
| 2026 Q1 | 1 | 0%none of 1 question | 1 |
| 2026 Q2 | 1 | 0%none of 1 question | 1 |
- 2024 Q42 questions · challenge rate 0% (none of 2 questions) · 1 company
- 2025 Q12 questions · challenge rate 0% (none of 2 questions) · 1 company
- 2025 Q21 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q31 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q41 question · challenge rate 0% (none of 1 question) · 1 company
- 2026 Q11 question · challenge rate 0% (none of 1 question) · 1 company
- 2026 Q21 question · challenge rate 0% (none of 1 question) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Capex Investment5
- Demand3
- Revenue Growth3
- Guidance Reliability3
- Geographic Expansion1
- Supply Chain1
- Margin1
- Cost Pressure1